Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
38.6
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPNet Sales6,484¥ millionYear on year +38.6%Progress 19.6%
Operating profit74¥ millionYear on year -79.0%Progress 2.6%
Ordinary income19¥ millionYear on year -92.9%Progress 0.7%
Net income attributable to owners of the parent369¥ millionYear on year -10.3%Progress 22.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥10.33
Financial position at period-end
Total assets65,164,890¥ thousand
of which net assets 22,165,183 ¥ thousandEquity ratio 32.1%vs. prior year-end +0.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueComprehensive Medical Management Support Business ¥2,359,973 thousand (YoY +83.8%), Senior-Related Businesses ¥2,068,245 thousand (YoY +19.3%), Highly Controlled Medical Devices Business ¥1,935,394 thousand (YoY +24.1%), Other ¥120,882 thousand (YoY +21.6%)
Segment profitComprehensive Medical Management Support Business ¥177,215 thousand (YoY -55.8%), Senior-Related Businesses ¥131,461 thousand (YoY +49.7%), Highly Controlled Medical Devices Business ¥143,271 thousand (YoY -6.4%), Other ¥-16,095 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥33,035 million (YoY +33.6%)
Operating profit¥2,864 million (YoY +21.1%)
Ordinary income¥2,648 million (YoY +23.9%)
Net income¥1,658 million (YoY -40.3%)
Annual Dividend Forecast¥0 → ¥0（0.0%）
Factors Behind Changes in Business Performance
Net sales increased due to the expansion of the scope of consolidation following M&A in the previous fiscal year, the acquisition of the colored contact lens business, and strong sales of private-label products. Operating income decreased due to a ¥688,162 thousand increase in selling, general and administrative expenses resulting from strategic upfront investments, as well as higher cost of sales caused by surging raw material prices.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 株式会社リリフル / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Gain on sale of non-current assets ¥49 thousand, Extraordinary Losses ¥32,482 thousand, Other ¥143 thousand
Depreciation and amortization¥237,980 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End37,982,900
Treasury Shares at Period-End2,173,600
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥6,484 million (YoY +38.6%) |
| Operating profit | ¥74 million (YoY -79.0%) |
| Ordinary income | ¥19 million (YoY -92.9%) |
| Profit attributable to owners of the parent | ¥369 million (YoY -10.3%) |
| Net income per share | ¥10.33 |
| Equity ratio | End of the current fiscal period 32.1 / End of previous period 31.5 |
| Total assets | ¥65,164,890 thousand |
| Net assets | ¥22,165,183 thousand |
| Full-year earnings forecast | Net Sales ¥33,035 million (YoY +33.6%) / Operating profit ¥2,864 million (YoY +21.1%) / Ordinary income ¥2,648 million (YoY +23.9%) / Net income ¥1,658 million (YoY -40.3%) |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Comprehensive Medical Management Support Business ¥2,359,973 thousand (YoY +83.8%), Senior-Related Businesses ¥2,068,245 thousand (YoY +19.3%), Highly Controlled Medical Devices Business ¥1,935,394 thousand (YoY +24.1%), Other ¥120,882 thousand (YoY +21.6%) |
| Segment profit | Comprehensive Medical Management Support Business ¥177,215 thousand (YoY -55.8%), Senior-Related Businesses ¥131,461 thousand (YoY +49.7%), Highly Controlled Medical Devices Business ¥143,271 thousand (YoY -6.4%), Other ¥-16,095 thousand |
| Depreciation and amortization | ¥237,980 thousand |
| Breakdown of extraordinary income (loss) | Gain on sale of non-current assets ¥49 thousand, Extraordinary Losses ¥32,482 thousand, Other ¥143 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社リリフル / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 37,982,900 |
| Treasury Shares at Period-End | 2,173,600 |
| Factors Behind Changes in Business Performance | Net sales increased due to the expansion of the scope of consolidation following M&A in the previous fiscal year, the acquisition of the colored contact lens business, and strong sales of private-label products. Operating income decreased due to a ¥688,162 thousand increase in selling, general and administrative expenses resulting from strategic upfront investments, as well as higher cost of sales caused by surging raw material prices. |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decline in operating income was due to a ¥688,162 thousand year-on-year increase in selling, general and administrative expenses resulting from strategic upfront investments to strengthen the foundation for medium- to long-term growth. In addition, cost of sales increased because of higher raw material prices for highly controlled medical devices and other products.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.